Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 6, 42

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency


Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Steven Simoens. Orphanet J Rare Dis.


Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, legislators, health care professionals, industry leaders, academics and patients. This study aims to conduct a literature review to provide insight into the drivers of orphan drug pricing and reimbursement. Although orphan drug pricing follows the same economic logic as drug pricing in general, the monopolistic power of orphan drugs results in high prices: a) orphan drugs benefit from a period of marketing exclusivity; b) few alternative health technologies are available; c) third-party payers and patients have limited negotiating power; d) manufacturers attempt to maximise orphan drug prices within the constraints of domestic pricing and reimbursement policies; and e) substantial R&D costs need to be recouped from a small number of patients. Although these conditions apply to some orphan drugs, they do not apply to all orphan drugs. Indeed, the small number of patients treated with an orphan drug and the limited economic viability of orphan drugs can be questioned in a number of cases. Additionally, manufacturers have an incentive to game the system by artificially creating monopolistic market conditions. Given their high price for an often modest effectiveness, orphan drugs are unlikely to provide value for money. However, additional criteria are used to inform reimbursement decisions in some countries. These criteria may include: the seriousness of the disease; the availability of other therapies to treat the disease; and the cost to the patient if the medicine is not reimbursed. Therefore, the maximum cost per unit of outcome that a health care payer is willing to pay for a drug could be set higher for orphan drugs to which society attaches a high social value. There is a need for a transparent and evidence-based approach towards orphan drug pricing and reimbursement. Such an approach should be targeted at demonstrating the relative effectiveness, cost-effectiveness and economic viability of orphan drugs with a view to informing pricing and reimbursement decisions.


Figure 1
Figure 1
Association between annual Belgian cost per patient of an orphan drug and disease prevalence.

Similar articles

See all similar articles

Cited by 51 articles

See all "Cited by" articles


    1. European Commission. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities. 2000. L 18/1.
    1. Orphanet. The portal for rare diseases and orphan drugs. Orphanet. 2011. pp. 9–5. 2011. Ref Type: Electronic Citation.
    1. Alcimed. Study on orphan drugs. Phase I: overview of the conditions for marketing orphan drugs in Europe. Koning Boudewijnstichting. 2006. pp. 18–3. 2010. Ref Type: Electronic Citation.
    1. Denis A, Simoens S, Fostier C, Mergaert L, Cleemput I. Health technology assessment policy governing orphan diseases and orphan medicines. Brussels, Belgian Health Care Knowledge Centre; 2009. Ref Type: Report.
    1. Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov. 2010;9:921–929. doi: 10.1038/nrd3275. - DOI - PubMed